See more : Portale Sardegna S.p.A. (PSA.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Summit Therapeutics Inc. (SMMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Summit Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- URA Holdings Plc (URAH.L) Income Statement Analysis – Financial Results
- Abhotel Co., Ltd. (6565.T) Income Statement Analysis – Financial Results
- Topsports International Holdings Limited (6110.HK) Income Statement Analysis – Financial Results
- Proto Labs, Inc. (PRLB) Income Statement Analysis – Financial Results
- Eneco Refresh Limited (ERG.AX) Income Statement Analysis – Financial Results
Summit Therapeutics Inc. (SMMT)
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 704.30K | 1.81M | 860.00K | 632.02K | 56.41M | 35.98M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 2.77M | 1.21M | 301.95K | 266.64K | 6.03M | 2.03M | 947.89K | 212.76K | 1.82K |
| Cost of Revenue | 2.05M | 2.51M | 0.00 | 0.00 | 155.40K | 24.92K | 97.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 5.77K | 2.51M | 596.30K | 415.93K | 169.46K | 1.82K |
| Gross Profit | -2.05M | -1.81M | 1.81M | 860.00K | 476.62K | 56.39M | 35.88M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 1.77M | 1.21M | 301.95K | 260.87K | 3.51M | 1.43M | 531.96K | 43.31K | 0.00 |
| Gross Profit Ratio | 0.00% | -256.95% | 100.00% | 100.00% | 75.41% | 99.96% | 99.73% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 63.68% | 100.00% | 100.00% | 97.84% | 58.28% | 70.60% | 56.12% | 20.35% | 0.00% |
| Research & Development | 59.47M | 52.00M | 85.35M | 53.27M | 32.71M | 51.38M | 41.01M | 23.69M | 23.94M | 15.64M | 10.83M | 5.72M | 4.78M | 3.66M | 3.68M | 7.38M | 15.34M | 5.79M | 1.83M | 504.60K | 0.00 |
| General & Administrative | 30.27M | 26.70M | 23.61M | 19.23M | 7.24M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 3.83M | 3.91M | 5.14M | 863.07K | 1.79M | 75.31K | 43.79K |
| Selling & Marketing | -2.05M | 0.00 | 0.00 | 0.00 | 2.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.24K | 1.12M | 2.17M | 1.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 28.22M | 26.70M | 23.61M | 19.23M | 9.30M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 4.20M | 5.03M | 7.31M | 1.86M | 1.79M | 75.31K | 43.79K |
| Other Expenses | 0.00 | -14.42M | -20.97M | -19.31M | 0.00 | -19.88M | -3.86M | -1.95M | -3.14M | -682.90K | -682.90K | 18.95K | 339.19K | -10.32M | 3.48M | 2.97M | 2.70M | 2.37M | 119.60K | 0.00 | -1.82K |
| Operating Expenses | 87.69M | 64.28M | 88.00M | 53.19M | 42.00M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 26.92M | 10.03M | 3.74M | 579.92K | 43.79K |
| Cost & Expenses | 89.74M | 64.28M | 88.00M | 53.19M | 43.40M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 29.43M | 10.62M | 4.16M | 749.37K | 45.61K |
| Interest Income | 10.40M | 1.51M | 178.95K | 4.00K | 4.34K | 3.66M | 4.38M | 10.00K | 30.00K | 0.00 | 14.85K | 17.37K | 10.99K | 26.90K | 12.78K | 430.95K | 1.54M | 1.72M | 1.04M | 404.81K | 1.82K |
| Interest Expense | 16.46M | 4.40M | 281.00K | 255.00K | 32.52K | 556.10K | 1.65M | 1.08M | 0.00 | 448.00K | 0.00 | 0.00 | 4.71K | 6.33K | 107.04K | 116.74K | 75.56K | 11.77K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 90.74M | 2.51M | 2.46M | 2.00M | 1.39M | 1.49M | 348.21K | 72.50K | 68.36K | 49.72K | 42.89K | 146.89K | 295.22K | 710.54K | 3.78M | 2.74M | 3.28M | 737.53K | 240.99K | 9.41K | 1.82K |
| EBITDA | 1.00M | -52.63M | -62.74M | -37.13M | -16.80M | 11.66M | -32.19M | -30.98M | -20.30M | -12.20M | -11.02M | -5.48M | -4.41M | -8.65M | -5.41M | -16.03M | -18.58M | -6.13M | -2.97M | -527.20K | -41.96K |
| EBITDA Ratio | 0.00% | -8,633.17% | -4,764.29% | -5,985.47% | -6,546.15% | 24.59% | -37.31% | -1,075.82% | 0.00% | -854.30% | -486.04% | -191.35% | -157.79% | -298.82% | -1,786.78% | -4,499.47% | -308.42% | -302.42% | -203.69% | -57.52% | -2,300.00% |
| Operating Income | -89.74M | -72.09M | -86.19M | -53.19M | -42.76M | 12.38M | -18.25M | -31.07M | -28.73M | -19.15M | -11.07M | -7.23M | -4.71M | -9.38M | -9.20M | -19.20M | -23.40M | -8.60M | -3.21M | -536.61K | -43.79K |
| Operating Income Ratio | 0.00% | -10,235.63% | -4,764.29% | -6,185.23% | -6,766.39% | 21.95% | -50.73% | -1,078.69% | 0.00% | -844.40% | -487.93% | -252.32% | -170.09% | -777.06% | -3,047.63% | -7,198.94% | -388.45% | -423.79% | -338.91% | -252.21% | -2,400.00% |
| Total Other Income/Expenses | -526.14M | -19.15M | -24.87M | -14.01M | -1.04M | -3.30M | 1.91M | -854.00K | 5.54M | -427.00K | 14.85K | 17.37K | 6.28K | 20.57K | -94.26K | 314.20K | 1.47M | 1.71M | 1.04M | 404.81K | 1.82K |
| Income Before Tax | -615.87M | -78.78M | -88.60M | -52.91M | -28.41M | 6.60M | -15.42M | -32.13M | -28.69M | -19.07M | -11.05M | -7.21M | -4.71M | -9.36M | -9.30M | -18.88M | -21.94M | -6.88M | -2.17M | -131.80K | -41.96K |
| Income Before Tax Ratio | 0.00% | -11,185.94% | -4,897.84% | -6,152.33% | -4,494.86% | 11.70% | -42.85% | -1,115.76% | 0.00% | -841.02% | -487.27% | -251.71% | -169.86% | -775.36% | -3,078.84% | -7,081.10% | -364.13% | -339.36% | -229.12% | -61.95% | -2,300.00% |
| Income Tax Expense | -946.00K | -4.40M | -2.46M | -213.00K | -4.52M | -3.27M | -5.32M | -5.42M | -4.36M | -1.95M | -1.00M | -538.61K | -477.37K | -1.94M | -594.31K | -2.52M | -1.81M | -959.18K | -278.48K | -45.19K | -1.82K |
| Net Income | -614.93M | -74.38M | -86.15M | -52.70M | -23.88M | 9.87M | -10.09M | -26.71M | -24.34M | -17.12M | -10.05M | -6.67M | -4.23M | -7.42M | -8.66M | -32.29M | -20.13M | -5.92M | -1.89M | -86.61K | -41.96K |
| Net Income Ratio | 0.00% | -10,561.06% | -4,762.13% | -6,127.56% | -3,779.08% | 17.50% | -28.05% | -927.56% | 0.00% | -754.85% | -443.13% | -232.91% | -152.63% | -614.68% | -2,867.20% | -12,109.76% | -334.06% | -292.07% | -199.74% | -40.71% | -2,300.00% |
| EPS | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.16 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| EPS Diluted | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.15 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.03M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
| Weighted Avg Shares Out (Dil) | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.43M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Summit Therapeutics (SMMT 5.82%) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its...
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III results for ivonescimab versus KEYTRUDA in first-line NSCLC are...
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Do you ever wonder what America's wealthiest stock traders are buying and selling? Thanks to the Securities and Exchange Commission, you don't have to.
Warning: This Skyrocketing Stock Has a Hidden Risk
Up 860% in the last 12 months alone, Summit Therapeutics (SMMT -2.53%) is a skyrocketing stock that likely has more upside in store.
Summit Therapeutics to Present at Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference, both being held in Miami. Our...
3 Monster Stocks in the Making
3 Monster Stocks in the Making
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new...
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works.
Why Summit Therapeutics Stock Was a Winner Today
A cancer drug has vast potential for the company, says a pundit newly following it.
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5...
Source: https://incomestatements.info
Category: Stock Reports